This award will help research, validate and implement a new model for sharing and integrating data at a national level.

Evan Weber will use this “high risk, high reward” grant to fund research into improving CAR-T therapies.

Researchers at Children’s Hospital of Philadelphia (CHOP) revealed for the first time that children, adolescents and young adults may experience very rare neurological issues of paraparesis and quadriparesis following chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy used to treat B-cell Acute Lymphoblastic Leukemia (B-ALL). Additionally, these complications occurred without the type of inflammation typically seen in adults. The findings were published today in the journal Blood.

CHOP researchers are aiming to treat a wider range of cancers by reaching previously “unreachable” drug targets.

Researchers in the Children’s Oncology Group (COG) at Children’s Hospital of Philadelphia (CHOP) are highlighting key factors influencing survival rates after the first relapse of acute lymphoblastic leukemia (ALL) in children. The study, which is the largest of its kind to evaluate leukemia relapse in children, was published recently in the journal Leukemia.

Dr. Adam Wolpaw and Dr. Timothy Spear of Children's Hospital of Philadelphia (CHOP) received the Scholar Hope Award and Young Investigator Award respectively from Hyundai Hope On Wheels.

Researchers at Children’s Hospital of Philadelphia (CHOP) demonstrated a promising new approach in the fight against high-risk neuroblastoma, a common and potentially deadly childhood cancer that can occur within the peripheral nervous system. The study, recently published in Nature Communications, found that chimeric antigen receptor (CAR) T-cell therapy targeting two markers on neuroblastoma cancer cells simultaneously boosted overall immune response by engaging adaptive and innate immunity in preclinical models.

Researchers at Children’s Hospital of Philadelphia (CHOP), St. Jude Children’s Research Hospital (St. Jude) and the Children’s Oncology Group (COG) today announced a significant paradigm shift in the understanding of T-lineage acute lymphoblastic leukemia (T-ALL), an aggressive and high-risk form of cancer, to one frequently driven by genetic changes in non-coding portions of our DNA. The collaborative study, supported by the Gabriella Miller Kids First Pediatric Research Program (Kids First) and National Institutes of Health (NIH) Common Fund, was published today in the journal Nature.

Researchers at Children’s Hospital of Philadelphia (CHOP) announced a significant breakthrough in understanding chemotherapy resistance in high-risk neuroblastoma, a common and potentially deadly childhood cancer arising within the peripheral nervous system.

Dr. David Teachey, attending physician and Distinguished Endowed Chair in the Department of Pediatrics at Children’s Hospital of Philadelphia (CHOP), has been appointed Chair of the Acute Lymphoblastic Leukemia (ALL) Disease Committee in the Children’s Oncology Group (COG).